139 related articles for article (PubMed ID: 15250065)
1. Ten years of alendronate treatment for osteoporosis in postmenopausal women.
Chan AS
N Engl J Med; 2004 Jul; 351(2):190-2; author reply 190-2. PubMed ID: 15250065
[No Abstract] [Full Text] [Related]
2. Alendronate and parathyroid hormone.
Muldowney FP
N Engl J Med; 2005 Dec; 353(24):2618-9; author reply 2618-9. PubMed ID: 16354902
[No Abstract] [Full Text] [Related]
3. The patient's page. Bone health facts.
McKinney J
South Med J; 2005 Oct; 98(10):1058. PubMed ID: 16295830
[No Abstract] [Full Text] [Related]
4. Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women.
Ishijima M; Sakamoto Y; Yamanaka M; Tokita A; Kitahara K; Kaneko H; Kurosawa H
Calcif Tissue Int; 2009 Nov; 85(5):398-404. PubMed ID: 19795092
[TBL] [Abstract][Full Text] [Related]
5. A review of osteoporosis management in younger premenopausal women.
McLendon AN; Woodis CB
Womens Health (Lond); 2014 Jan; 10(1):59-77. PubMed ID: 24328599
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
Roux C; Binkley N; Boonen S; Kiel DP; Ralston SH; Reginster JY; Pong A; Rosenberg E; Santora A;
Calcif Tissue Int; 2014 Feb; 94(2):153-7. PubMed ID: 23912950
[TBL] [Abstract][Full Text] [Related]
7. Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis.
Fuller KE
N Engl J Med; 2004 Jan; 350(2):189-92; author reply 189-92. PubMed ID: 14714278
[No Abstract] [Full Text] [Related]
8. Vitamin D Boosts Alendronate Tail Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis.
Catalano A; Bellone F; Santoro D; Schwarz P; Gaudio A; Basile G; Sottile MC; Stoian SA; Corica F; Morabito N
Nutrients; 2021 May; 13(6):. PubMed ID: 34072655
[TBL] [Abstract][Full Text] [Related]
9. Summaries for patients. Alendronate improves osteoporosis in elderly women living in long-term care facilities.
Ann Intern Med; 2002 May; 136(10):I54. PubMed ID: 12020160
[No Abstract] [Full Text] [Related]
10. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Ringe JD; Farahmand P; Schacht E; Rozehnal A
Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
[TBL] [Abstract][Full Text] [Related]
11. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis.
Eviö S; Tiitinen A; Laitinen K; Ylikorkala O; Välimäki MJ
J Clin Endocrinol Metab; 2004 Feb; 89(2):626-31. PubMed ID: 14764773
[TBL] [Abstract][Full Text] [Related]
12. Assessment of eldecalcitol and alendronate effect on postural balance control in aged women with osteoporosis.
Suzuki T; Harada A; Shimada H; Hosoi T; Kawata Y; Inoue T; Saito H
J Bone Miner Metab; 2020 Nov; 38(6):859-867. PubMed ID: 32719981
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D status and response to daily 400 IU vitamin D3 and weekly alendronate 70 mg in men and women with osteoporosis.
Karaplis AC; Chouha F; Djandji M; Sampalis JS; Hanley DA
Ann Pharmacother; 2011 May; 45(5):561-8. PubMed ID: 21521859
[TBL] [Abstract][Full Text] [Related]
14. [Vitamin D supplements. Recommended doses are not enough].
Díez Pérez A
Med Clin (Barc); 2012 Mar; 138(5):202-3. PubMed ID: 22197369
[No Abstract] [Full Text] [Related]
15. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Black DM; Greenspan SL; Ensrud KE; Palermo L; McGowan JA; Lang TF; Garnero P; Bouxsein ML; Bilezikian JP; Rosen CJ;
N Engl J Med; 2003 Sep; 349(13):1207-15. PubMed ID: 14500804
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
Nogues X; Servitja S; Peña MJ; Prieto-Alhambra D; Nadal R; Mellibovsky L; Albanell J; Diez-Perez A; Tusquets I
Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
[TBL] [Abstract][Full Text] [Related]
17. Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.
Panico A; Lupoli GA; Fonderico F; Marciello F; Martinelli A; Assante R; Lupoli G
Thyroid; 2009 May; 19(5):437-42. PubMed ID: 19415993
[TBL] [Abstract][Full Text] [Related]
18. Ten years' experience with alendronate for osteoporosis in postmenopausal women.
Bone HG; Hosking D; Devogelaer JP; Tucci JR; Emkey RD; Tonino RP; Rodriguez-Portales JA; Downs RW; Gupta J; Santora AC; Liberman UA;
N Engl J Med; 2004 Mar; 350(12):1189-99. PubMed ID: 15028823
[TBL] [Abstract][Full Text] [Related]
19. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
20. Ten years of alendronate treatment for osteoporosis in postmenopausal women.
Ott SM
N Engl J Med; 2004 Jul; 351(2):190-2; author reply 190-2. PubMed ID: 15250064
[No Abstract] [Full Text] [Related]
[Next] [New Search]
